NOTE: This disposition is nonprecedential.
United States Court of Appeals for the Federal Circuit
2007-1299
MONSANTO COMPANY,
Plaintiff-Appellee,
v.
BAYER BIOSCIENCE N.V.,
Defendant-Appellant.
Susan K. Knoll, Howrey LLP, of Houston, Texas, argued for plaintiff-appellee. With
her on the brief were Richard L. Stanley, Steven G. Spears, and Michelle C. Replogle, of
Houston, Texas, and Daniel T. Shvodian, of East Palo Alto, California.
George Pazuniak, Womble Carlyle Sandridge & Rice, PLLC, of Wilmington,
Delaware, argued for defendant-appellant. With him on the brief were James M. Lennon
and Anna Martina Linnea Tyreus, of Wilmington, Delaware, and Virginia Whitne Hoptman,
of Tysons Corner, Virginia. Of counsel was Timothy G. Barber, of Charlotte, North
Carolina.
Appealed from: United States District Court for the Eastern District of Missouri
Judge E. Richard Webber
NOTE: This disposition is nonprecedential.
United States Court of Appeals for the Federal Circuit
2007-1299
MONSANTO COMPANY,
Plaintiff-Appellee,
v.
BAYER BIOSCIENCE N.V.,
Defendant-Appellant.
Appeal from the United States District Court for the Eastern District of Missouri in case
no. 4:00-CV-01915, Judge E. Richard Webber.
___________________________
DECIDED: April 23, 2008
___________________________
Before BRYSON, GAJARSA, and LINN, Circuit Judges.
PER CURIAM.
In 2000 Plaintiff-Appellee Monsanto Co. (“Monsanto”) brought a declaratory
judgment action against Defendant-Appellant Bayer Bioscience N.V. (“Bayer”)
challenging the validity and unenforceablity of four Bayer patents, U.S. Patent Nos.
5,545,565 (“the ’565 patent”), 5,767,372 (“the ’372 patent”), 6,107,546 (“the ’546
patent”), and 5,254,799 (“the ’799 patent”), and asserting that Monsanto’s transgenic
corn products did not infringe these patents. The case is now before us for the third
time. For the reasons stated below, we affirm.
Most recently, in Appeal No. 2007-1109, Bayer appealed the final judgment
issued after jury trial and a bench trial declaring the asserted claims of the ’565 patent
invalid and non-infringed, and holding all four patents unenforceable for inequitable
conduct. Monsanto v. Bayer Bioscience N.V., 514 F.3d 1229 (Fed. Cir. 2008)
(Monsanto III). A panel of this court affirmed on the grounds that the district court did
not err in holding the four patents unenforceable for inequitable conduct. We upheld the
inequitable conduct ruling with regards to the ’565 patent because there was no clear
error in the district court finding Bayer failed to disclose material information regarding
the ’565 patent with an intent to deceive the PTO during the prosecution of the patent.
Id. at 1241-42. In addition, we rejected Bayer’s arguments that the district court was
without jurisdiction to declare the ’372, ’546, and ’799 patents unenforceable for
inequitable conduct. Id. at 1242-43. In light of Bayer’s failure to challenge the merits of
the district court’s inequitable conduct findings regarding these three patents, we
therefore also affirmed the district court’s inequitable conduct findings for these patents.
Id. at 1243 n.18 (“Bayer does not, in this appeal, challenge the district court’s findings of
inequitable conduct regarding the ’799, ’372, and ’546 patents. Therefore, those findings
are affirmed.”); see Engel Indus., Inc. v. Lockformer Co., 166 F.3d 1379, 1383 (Fed. Cir.
1999) (“An issue that falls within the scope of the judgment appealed from but is not
raised by the appellant in its opening brief on appeal is necessarily waived.”).
In the current appeal, Bayer appeals the final judgment of the district court
granting attorney fees to Monsanto under 35 U.S.C. § 285. The district court concluded
that attorney fees were warranted because Bayer’s inequitable conduct in the
prosecution of the four patents made the case exceptional. See 35 U.S.C. § 285
2007-1299 2
(allowing for award of attorney’s fees in “exceptional cases”); Brasseler, U.S.A. I, L.P. v.
Stryker Sales Corp., 267 F.3d 1370, 1380 (Fed. Cir. 2001) (holding that a party may
prove the existence of an exceptional case by showing inequitable conduct before the
PTO).
Whether a case is exceptional under § 285 is a factual question reviewed for
clear error. Cybor Corp. v. FAS Techs., 138 F.3d 1448, 1460 (Fed. Cir. 1998). The
district court’s decision to award attorney fees after finding a case exceptional is
reviewed for abuse of discretion. Id. In the instant case, Bayer does not challenge the
discretionary determination to award attorney fees. Rather, Bayer argues only that the
district court erred in finding that each of the four patents was procured through
inequitable conduct.
The law of the case “prevent[s] the relitigation of issues that have been decided”
absent narrow exceptional circumstances. Gould, Inc. v. United States, 67 F.3d 925,
930 (Fed. Cir. 1995) (quoting Jamesbury Corp. v. Litton Indus. Prods., Inc., 839 F.2d
1544, 1550 (Fed. Cir. 1998)). Under the law of the case doctrine “a court adheres to a
decision in a prior appeal in the same case unless one of three exceptional
circumstances exist: (1) the evidence in a subsequent trial is substantially different;
(2) controlling authority has since made a contrary decision of the law applicable to the
issues; or (3) the earlier ruling was clearly erroneous and would work a manifest
injustice.” Id.
Bayer already appealed the district court’s judgment that all four patents were
unenforceable for inequitable conduct in the 2007-1109 appeal, and in the disposition of
that appeal this court explicitly affirmed the district court’s findings that there was
2007-1299 3
inequitable conduct in the prosecution of each of the four patents. Monsanto III, 514
F.3d at 1241-42,1243 n.18. As none of the exceptions to the law of the case applies, we
cannot revisit our prior holding. Bayer has presented no other argument for reversing
the district court’s grant of attorney’s fees. Accordingly, the judgment of the district court
is affirmed.
Costs to Appellee.
2007-1299 4